Orion b Aktie
42,43EUR | 0,14EUR | 0,33% |
WKN DE: A0J3QM / ISIN: FI0009014377
Aktionärsstruktur
Inhaber | in % |
---|---|
Freefloat | 96,44 |
Keskinäinen Työeläkevakuutusyhtiö Varma | 4,27 |
Keskinäinen Eläkevakuutusyhtiö Ilmarinen | 3,55 |
Government Pension Fund - Global (The) | 2,81 |
Keskinäinen Työeläkevakuutusyhtiö Elo | 1,70 |
Vanguard Total International Stock Index Fund | 1,37 |
OP Asset Management Ltd. | 1,18 |
Valtion Eläkerahasto - The State Pension Fund | 1,11 |
The Social Insurance Institution of Finland (Invt Port) | 0,93 |
Sp-Fund Management Co. Ltd. | 0,86 |
OP Suomi | 0,85 |
Vanguard Developed Markets Index Fund | 0,85 |
Vanguard Institutional Total Intl. Stock Market Index Tr. II | 0,68 |
Orion Oyj | 0,58 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Personal am Ende des Jahres | 3 265 | 3 311 | 3 355 | 3 527 | 3 632 |
Umsatz pro Mitarbeiter in Mio. EUR | 0,32 | 0,33 | 0,31 | 0,38 | 0,33 |
Bilanz (in Mio. EUR) - Aktiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Umlaufvermögen | 600 | 744 | 690 | 879 | 825 |
Summe Anlagevermögen | 436 | 372 | 424 | 625 | 621 |
Summe Aktiva | 1 036 | 1 116 | 1 114 | 1 504 | 1 446 |
Bilanz (in Mio. EUR) - Passiva
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Summe Fremdkapital | 256 | 384 | 366 | 596 | 556 |
Summe Eigenkapital | 779 | 731 | 748 | 908 | 890 |
Summe Passiva | 1 036 | 1 116 | 1 114 | 1 504 | 1 446 |
Adresse
Orionintie 1A, 02200 Espoo | |
Telefon | +358 (10) 4261 |
Internet | http://www.orion.fi |
Management
Aino Anna Liisa Hurme
President & Chief Executive Officer |
Ari Tapio Lehtoranta
Independent Director |
Eija Ronkainen
Independent Director |
Heikki Joensuu
Vice President-Therapy Area Oncology, R&D |
Henrik Stenqvist
Director |
Hilpi Rautelin
Vice Chairman |
Johanna Ivaska
Dir-Orion Rsch Center for Biotech & Trnsltnl Rsch |
Juhani Kankaanpaa
Senior Vice President-Global Operations |
Jukka Muhonen
Director-Global Business Development |
Julia Macharey
Senior Vice President-People & Culture |
Karen Lykke Sörensen
Director |
Kari Jussi Aho
Independent Director |
Maziar Mike Doustdar
Director |
Mikko Kemppainen
Head-Legal Affairs |
Olli Huotari
Secretary & Senior VP-Corporate Functions |
Outi Vaarala
SVP-Innovative Medicines, Research & Development |
Paula Rytilä
Head-Region Asia Pacific |
René Lindell
Chief Financial Officer |
Satu Maarit Ahomäki
Senior VP-Generics & Consumer Health |
Sinikka Markkula
Chief Information Officer |
Tero Närvänen
Vice President-Quality Management |
Tuukka Hirvonen
Head-Investor Relations |
Veli-Matti Johannes Mattila
Chairman |